Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POVAN vs ANTEPAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Treatment of enterobiasis (pinworm infection) caused by Enterobius vermicularis
Treatment of ascariasis (roundworm infection),Treatment of enterobiasis (pinworm infection)
Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
Terminal elimination half-life is approximately 16 hours; clinically, this supports single-dose administration with slow elimination
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Pyrvinium pamoate is minimally absorbed from the gastrointestinal tract; systemic metabolism is negligible. The small absorbed fraction is metabolized in the liver, but specific enzymes are not well defined.
Partially metabolized in the liver; some metabolites are excreted unchanged.
Primarily fecal (90%) as unchanged drug via bile; renal excretion is minimal (<1%)
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Bound to plasma proteins (especially albumin) approximately 75–80%
Approximately 90% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is 0.5–0.7 L/kg, consistent with moderate tissue distribution
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water.
Oral bioavailability is low (<10%) due to poor absorption; acts topically in the GI tract
Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism.
No specific guidelines; caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis.
Contraindicated in acute hepatic disease or significant liver impairment (Child-Pugh class B or C); use not recommended.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%.
Weight-based: 11 mg/kg (maximum 1 g) orally once for pinworm; repeat in 2 weeks. For other infections: 11 mg/kg once daily for 3 days.
Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg.
No specific adjustments; use standard dosing with caution due to potential comorbidities and reduced hepatic function.
Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment.
None
None.
Gastrointestinal disturbances may occur; caution in patients with inflammatory bowel disease or severe hepatic impairment. May cause staining of stools and emesis. Avoid in pregnancy unless clearly needed.
Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses.
Hypersensitivity to pyrvinium or any component of the formulation,Intestinal obstruction or acute abdominal conditions
Hypersensitivity to piperazine; patients with pre-existing neurological disorders such as epilepsy.
No specific food interactions. The drug should be taken with food to reduce gastrointestinal upset.
No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs.
Pyrvinium pamoate (Povan) is not recommended during pregnancy due to insufficient human data. Animal studies have not shown teratogenicity, but risk cannot be excluded. In first trimester, avoid use unless clearly needed. Second and third trimester: consider risk-benefit; no known fetal harm from limited reports.
ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed.
Unknown if pyrvinium pamoate is excreted in human milk. M/P ratio not available. Caution advised, consider alternative treatment during breastfeeding.
Piperazine is excreted into breast milk in small amounts. The M/P ratio is not established. The American Academy of Pediatrics considers piperazine compatible with breastfeeding, but caution is advised due to potential adverse effects in nursing infants. Use only if benefits outweigh risks.
No dose adjustment studied in pregnancy. Standard adult dose: 5 mg/kg base (max 350 mg) single dose. Use only if potential benefit justifies risk.
No specific dose adjustments recommended during pregnancy. Piperazine pharmacokinetics may be altered due to increased plasma volume and renal clearance, but standard dosing is generally used. Monitor for efficacy and adverse effects.
POVAN (pyrvinium pamoate) is primarily used for enterobiasis (pinworm infection). Administer as a single oral dose; repeat after 2 weeks to prevent reinfection. Tablets should be swallowed whole to avoid staining teeth. Drug may turn stools red. Avoid in patients with gastrointestinal disorders or inflammatory bowel disease. Monitor for nausea, vomiting, and cramping.
ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives.
Take the medication exactly as a single dose, and repeat after 2 weeks.,Swallow tablets whole; do not crush or chew to prevent mouth staining.,Stools may appear bright red; this is harmless.,Wash hands thoroughly after using the toilet and before eating to prevent reinfection.,Wash bedding and underwear in hot water; vacuum floors to remove eggs.,Treat all household members simultaneously to avoid spread.,Report persistent abdominal pain or diarrhea to your doctor.
Take exactly as prescribed; complete full course even if symptoms improve.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Report any muscle weakness, tremors, or confusion to your doctor immediately.,For pinworm infection, all household members should be treated to prevent reinfection.,Practice strict hand hygiene and wash bed linens in hot water to reduce spread.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POVAN vs ANTEPAR, answered by our medical review team.
POVAN is a Anthelmintic that works by Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.. ANTEPAR is a Anthelmintic that works by Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POVAN and ANTEPAR depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POVAN is: Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.. The standard adult dose of ANTEPAR is: Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POVAN and ANTEPAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POVAN is classified as Category C. Pyrvinium pamoate (Povan) is not recommended during pregnancy due to insufficient human data. Animal studies have not shown teratogenicity, but risk cannot be excluded. In first tr. ANTEPAR is classified as Category C. ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. Fir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.